Study of NMS-03305293 for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have small cell lung cancer that has spread and come back after at least one prior treatment, including immunotherapy, and also after tarlatamab if it was available for you.
- You have had no more than 3 prior cancer treatments overall.
- You are well enough to be up and about (ECOG score 0–2).
- Your cancer has grown on scans since your last treatment, and you have tumors that can be measured.
- You have waited at least 2 weeks (or longer depending on the drug) since your last cancer treatment, and any side effects (except hair loss) have mostly resolved.
- You can swallow capsules whole without chewing or crushing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new investigational drug (IBB0979) to the standard chemotherapy topotecan helps people with small cell lung cancer whose cancer has come back after earlier treatment. The goal is to see if the combination is more effective than topotecan alone.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
This trial tests a chemotherapy drug called nab-paclitaxel combined with other local treatments (like radiation) for people with small cell lung cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer and improves outcomes.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.